News

According to the agreement, Moderna will use BARDA’s funding to advance its mRNA-1273 vaccine candidate to FDA licensure. The mRNA-1273 is a vaccine candidate against SARS-CoV-2 encoding for

ONTRUZANT is available in both 150 mg single-dose vials and 420 mg multiple-dose vials. ONTRUZANT will be introduced in the U.S. at a list price (wholesaler acquisition cost)

FT-4202 is a potent activator of pyruvate kinase-R (PKR) that, in preclinical studies, demonstrated the potential to beneficially impact both anemia and vaso-occlusive crises for people living with

The deal is said to leverage TScan’s advanced platform to discover novel cancer antigens, which are expected to be targeted by TCR-based therapies. TScan chief scientific officer Gavin

The Chinese biopharmaceutical company said that it has been developing the COVID-19 vaccine candidate since January 2020. The firm claimed that its scientists have quickly completed comprehensive preclinical

The program will evaluate the safety and efficacy of Intensity’s lead product INT230-6, an investigational, novel and potent anti-cancer drug designed to directly kill cancer cells through intratumoral

According to the FDA, Fast Track designation is designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical

The companies have signed a letter of intent to enter into collaboration for the development of a novel coronavirus vaccine by using their technologies. GSK CEO Emma Walmsley

In this regard, Hope Biosciences will be evaluating the safety and efficacy of its adipose-derived mesenchymal stem cells (HB-adMSCs) in the mid-stage clinical trial. The phase 2 trial,